Aberrant methylation of secreted protein, acidic and rich in cysteine in human laryngeal and hypopharyngeal carcinoma

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 725-729

  He, Qian ^a   Wei, Jiazhang ^b   Zhang, Jinyan ^b   Jiang, Heng ^a   Wang, Shumin ^a   Zhou, Xiaoying ^a   Zhang, Zhe ^a   Huang, Guangwu ^a   Watanabe, Hiroshi ^b   Su, Jiping ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acidic and rich in cysteine; DNA methylation; Head and neck squamous cell carcinoma; Secreted protein; Tumor suppressor genes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; COMPLEMENTARY DNA; GENOMIC DNA; MOLECULAR MARKER; OSTEONECTIN; RNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 79958042031     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.297     Document Type: Article

References (24)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18: 581-592, 2007.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics,. CA Cancer J Clin 58: 71-96, 2008.
3. DeRienzo DP, Greenberg SD and Fraire AE: Carcinoma of the larynx. Changing incidence in women. Arch Otolaryngol Head Neck Surg 117: 681-684, 1991.
4. Chen YJ, Chang JT, Liao CT, Wang HM, Yen TC, Chiu CC, Lu YC, Li HF and Cheng AJ: Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 99: 1507-1514, 2008.
5. Rempel SA, Golembieski WA, Ge S, Lemke N, Elisevich K, Mikkelsen T and Gutierrez JA: SPARC: a signal of astrocytic neo-plastic transformation and reactive response in human primary and xenograft gliomas. J Neuropathol Exp Neurol 57: 1112-1121, 1998.
6. Seno T, Harada H, Kohno S, Teraoka M, Inoue A and Ohnishi T: Downregulation of SPARC expression inhibits cell migration and invasion in malignant gliomas. Int J Oncol 34: 707-715, 2009.
7. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J and Podhajcer OL: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 108: 210-214, 1997.
8. Horie K, Tsuchihara M and Nakatsura T: Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci 101: 913-919, 2010.
9. Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH and Goggins M: SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 22: 5021-5030, 2003.
10. Di Martino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, Yu R, Sikic BI, Raimondi SC and Dahl GV: Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 20: 426-432, 2006.
11. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC and Motamed K: Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 11: 126-13512, 2009.
12. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK and Kim H: Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121: 567-575, 2007.
13. Cheetham S, Tang MJ, Mesak F, Kennecke H, Owen D and Tai IT: SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response. Br J Cancer 98: 1810-1819, 2008.
14. Bull-Phelps SL, Carbon J, Miller A, Castro-Rivera E, Arnold S, Brekken RA and Lea JS: Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am J Obstet Gynecol 200: 180-187, 2009.
15. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR and Shin DM: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11: 6261-6269, 2005.
16. Olek A, Oswald J and Walter J: A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 24: 5064-5066, 1996.
17. Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R and El-Naggar AK: Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin Cancer Res 10: 3825-3830, 2004.
18. Bennett KL, Karpenko M, Lin MT, Claus R, Arab K, Dyckhoff G, Plinkert P, Herpel E, Smiraglia D and Plass C: Frequently methylated tumor suppressor genes in head and neck squamous cell carcinoma. Cancer Res 68: 4494-4499, 2008.
19. Bennett KL, Lee W, Lamarre E, Zhang X, Seth R, Scharpf J, Hunt J and Eng C: HPV status-independent association of alcohol and tobacco exposure or prior radiation therapy with promoter methylation of FUSSEL18, EBF3, IRX1, and SEPT9, but not SLC5A8, in head and neck squamous cell carcinomas. Genes Chromosomes Cancer 49: 319-326, 2010.
20. Choi P, Jordan CD, Mendez E, Houck J, Yueh B, Farwell DG, Futran N and Chen C: Examination of oral cancer biomarkers by tissue microarray analysis. Arch Otolaryngol Head Neck Surg 134: 539-546, 2008.
21. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG and Coman WB: Novel markers for poor prognosis in head and neck cancer. Int J Cancer 113: 789-797, 2005.
22. Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K and Gazdar AF: Aberrant methylation of SPARC in human lung cancers. Br J Cancer 92: 942-948, 2005.
23. Chen G, Tian X, Liu Z, Zhou S, Schmidt B, Henne-Bruns D, Bachem M and Kornmann M: Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression. Br J Cancer 102: 188-195, 2010.
24. Tang MJ and Tai IT: A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J Biol Chem 282: 34457-34467, 2007.